Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Atibuclimab - Implicit Bioscience

Next Previous
Drug Profile

Atibuclimab - Implicit Bioscience

Alternative Names: Anti-CD14 antibody; IC-14

Latest Information Update: 21 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ICOS Corporation
  • Developer ICOS Corporation; Implicit Bioscience; National Institute of Allergy and Infectious Diseases; University of Washington; Vanderbilt University Medical Center
  • Class Anti-infectives; Anti-inflammatories; Anti-ischaemics; Antibacterials; Monoclonal antibodies
  • Mechanism of Action CD14 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute lung injury; SARS-CoV-2 acute respiratory disease
  • Phase I/II Cardiomyopathies; Decompensated heart failure; Myocardial infarction
  • No development reported Motor neuron disease
  • Discontinued Septic shock

Most Recent Events

  • 06 Feb 2025 Phase-I/II clinical trials in Myocardial infarction in USA (IV) (NCT06678074)
  • 14 Nov 2024 Implicit Bioscience plans a phase I/II trial for Myocardial Infarction in USA (IV) (NCT06678074)
  • 17 Oct 2024 Phase-I/II clinical trials in Decompensated heart failure in USA (IV) (NCT06556810)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top